16,188 Pacira BioSciences, Inc. $PCRX Shares Acquired by Gagnon Securities LLC

Gagnon Securities LLC boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 624,805 shares of the company’s stock after purchasing an additional 16,188 shares during the quarter. Pacira BioSciences comprises approximately 2.7% of Gagnon Securities LLC’s investment portfolio, making the stock its 14th biggest position. Gagnon Securities LLC owned about 1.57% of Pacira BioSciences worth $15,651,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in Pacira BioSciences during the 1st quarter worth approximately $46,000. Global Retirement Partners LLC bought a new position in Pacira BioSciences during the second quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Pacira BioSciences during the third quarter worth about $51,000. State of Wyoming acquired a new stake in Pacira BioSciences in the 2nd quarter worth about $78,000. Finally, PNC Financial Services Group Inc. raised its stake in Pacira BioSciences by 15.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock worth $85,000 after purchasing an additional 492 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $36.46 on Thursday. The firm has a market capitalization of $1.46 billion, a P/E ratio of 23.39 and a beta of 0.21. The stock has a 50 day moving average price of $30.79 and a two-hundred day moving average price of $25.45. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $36.67. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.65 and a current ratio of 4.68.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.05). Pacira BioSciences had a return on equity of 10.82% and a net margin of 5.08%. The firm had revenue of $176.65 million for the quarter, compared to analysts’ expectations of $181.94 million. Equities analysts forecast that Pacira BioSciences, Inc. will post 1.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on PCRX shares. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 3rd. HC Wainwright cut shares of Pacira BioSciences from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $38.00 to $36.50 in a research report on Friday, October 9th. Wall Street Zen upgraded Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 26th. Royal Bank Of Canada lifted their price target on shares of Pacira BioSciences from $25.00 to $36.50 and gave the stock a “sector perform” rating in a report on Friday, October 9th. Finally, Oppenheimer assumed coverage on Pacira BioSciences in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $33.33.

Insider Transactions at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the sale, the insider directly owned 216,384 shares of the company’s stock, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total value of $217,920.00. Following the sale, the senior vice president directly owned 62,284 shares of the company’s stock, valued at approximately $2,262,154.88. This represents a 8.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.40% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences is a biopharmaceutical company focused on non-opioid approaches to pain management and related health needs. Its portfolio includes medicines and a device intended for use in surgical, musculoskeletal and other care settings. The company’s products include EXPAREL, a long-acting bupivacaine formulation used for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis pain; and the iovera system, which uses targeted cold to temporarily block peripheral nerves and relieve pain.